{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:42:58Z","timestamp":1793130178823,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.msard.2022.103669","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:01:04Z","timestamp":1643976064000},"page":"103669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis"],"prefix":"10.1016","volume":"59","author":[{"given":"Susana","family":"Sainz de la Maza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sabin Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Pilo de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Thuissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andreu\u2011V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gal\u00e1n S\u00e1nchez-Seco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Salgado-C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ayuso-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Garc\u00eda-Vasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda\u2011Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mart\u00ednez-Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mu\u00f1oz Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"D\u00edaz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"G\u00f3mez\u2011Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rubio-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Mar\u00eda","family":"Villar-Guimerans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-5452","authenticated-orcid":false,"given":"Yolanda","family":"Aladro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103669_bib0001","unstructured":"Tecfidera [package insert]. Cambridge, MA: Biogen, Inc; 2014."},{"issue":"4","key":"10.1016\/j.msard.2022.103669_bib0002","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1212\/NXI.0000000000001017","article-title":"Aggressive herpes zoster in young patients with multiple sclerosis under dimethyl fumarate significance of CD8+ and natural killer cells","volume":"8","author":"Anagnostouli","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2022.103669_bib0003","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.msard.2022.103669_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol. Clin. Pract."},{"issue":"12","key":"10.1016\/j.msard.2022.103669_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.103669_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nrl.2016.02.026","article-title":"Consensus statement on the treatment of multiple sclerosis by the Spanish Society of neurology in 2016","volume":"32","author":"Garc\u00eda Merino","year":"2017","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.msard.2022.103669_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"12","key":"10.1016\/j.msard.2022.103669_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2022.103669_bib0009","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1177\/1352458519866600","article-title":"Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS","volume":"26","author":"Granqvist","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103669_bib0010","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","author":"Jordan","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103669_bib0012","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"6","key":"10.1016\/j.msard.2022.103669_bib0013","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis","volume":"268","author":"Lucchini","year":"2021","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.103669_bib0014","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00415-018-8916-6","article-title":"Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study","volume":"265","author":"Mallucci","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103669_bib0015","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.103669_bib0016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103669_bib0017","series-title":"Common Terminology Criteria for Adverse Events","year":"2017"},{"issue":"12","key":"10.1016\/j.msard.2022.103669_bib0018","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s40263-020-00775-9","article-title":"Three-year effectiveness of dimethyl fumarate in multiple sclerosis: a prospective multicenter real-world study","volume":"34","author":"Pilo de la Fuente","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2022.103669_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.103669_bib0020","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103669_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2022.103669_bib0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822001845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822001845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:39Z","timestamp":1761901419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"alternative-id":["S2211034822001845"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103669","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103669"}}